Rivastigmine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00989 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 19 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | glaucoma | KG + DL |
| 2 | acute intermittent porphyria | KG + DL |
| 3 | psychogenic movement disorders | KG + DL |
| 4 | primary orthostatic tremor | KG + DL |
| 5 | tremor-nystagmus-duodenal ulcer syndrome | KG + DL |
| 6 | extrapyramidal and movement disease | KG + DL |
| 7 | benign shuddering attacks | KG + DL |
| 8 | benign paroxysmal tonic upgaze of childhood with ataxia | KG + DL |
| 9 | chronic tic disorder | KG + DL |
| 10 | primary hereditary glaucoma | KG + DL |
| 11 | lingual-facial-buccal dyskinesia | KG + DL |
| 12 | open-angle glaucoma | KG + DL |
| 13 | myoclonic dystonia | KG + DL |
| 14 | myoclonus-dystonia syndrome | KG + DL |
| 15 | torsion dystonia | KG + DL |
| 16 | early-onset generalized dystonia | KG + DL |
| 17 | X-linked dystonia-parkinsonism | KG + DL |
| 18 | torsion dystonia with onset in infancy | KG + DL |
| 19 | lethal infantile mitochondrial myopathy | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.